Last reviewed · How we verify

Desidustat Oral Tablet — Competitive Intelligence Brief

Desidustat Oral Tablet (Desidustat Oral Tablet) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PHD inhibitor. Area: Hematology.

phase 3 PHD inhibitor Prolyl hydroxylase domain-containing proteins (PHD) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Desidustat Oral Tablet (Desidustat Oral Tablet) — Zydus Lifesciences Limited. Desidustat inhibits prolyl hydroxylase domain-containing protein (PHD) enzymes to stabilize hypoxia-inducible factor (HIF) and increase endogenous erythropoietin production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Desidustat Oral Tablet TARGET Desidustat Oral Tablet Zydus Lifesciences Limited phase 3 PHD inhibitor Prolyl hydroxylase domain-containing proteins (PHD)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PHD inhibitor class)

  1. Zydus Lifesciences Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Desidustat Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/desidustat-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: